文献速递免疫规划

新型减毒带状疱疹疫苗NBP608与Zostavax®在50岁及以上健康成人中的免疫原性和安全性比较

Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older.
PubMed 文献 · Vaccine · 2019-05-20

该多中心随机双盲主动对照平行组试验在韩国评估新型减毒带状疱疹疫苗NBP608相对Zostavax®在50岁及以上健康成人中的免疫原性和安全性。823人接种(NBP608组413人,对照411人),接种后6周gpELISA抗体几何平均滴度NBP608低于对照,但ELISPOT无显著差异;6周内不良事件率组间无显著差异。

要点

  • NBP608接种后gpELISA几何平均滴度低于Zostavax®,调整GMT比0.80。
  • IFN-γ和IL-2 ELISPOT斑点形成数在6周时组间无显著差异。
  • 6周内不良事件率两组无显著差异,多数为轻度。

核心结论

  • NBP608在诱导免疫应答方面非劣于Zostavax®,可安全用于50岁及以上成人。

研究设计与样本

  • 多中心、随机、双盲、主动对照、平行组临床试验,在韩国开展。
  • 筛查845人,823人接种疫苗(NBP608组413人,对照Zostavax®组411人)。
  • 免疫原性于接种后6周以gpELISA和ELISPOT法评估,安全性监测26周。

主要发现

  • NBP608组gpELISA从基线至接种后的几何平均倍数上升为2.75 [95%CI (2.57, 2.94)]。
  • NBP608组与对照组的调整gpELISA几何平均滴度分别为1346.37 [95%CI (1273.99, 1422.87)]和1674.94 [95%CI (1585.35, 1769.58)]。
  • NBP608组相对对照组的调整GMT比值为0.80 [95%CI (0.75, 0.87)]。
  • 接种后6周IFN-γ和IL-2 ELISPOT几何平均斑点形成数在两组间无统计学显著差异(P值分别为0.7232和0.3844)。
  • 接种后6周内不良事件总发生率为49.82%(410/823, 941例),NBP608组为50.73%(209/412, 474例),对照组为48.91%(201/411, 467例),组间差异无统计学意义(P=0.6010)。

临床怎么用

  • NBP608可作为50岁及以上成人带状疱疹预防的候选疫苗,其免疫应答非劣于Zostavax®且安全性可接受。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A multi-centre, randomised, double-blinded, active-controlled, parallel-group clinical trial was carried out to assess the immunogenicity and safety of NBP608-a newly developed live-attenuated zoster vaccine in Korea-relative to Zostavax® in healthy adults aged 50 years or older. Immune responses to the vaccine were evaluated by glycoprotein enzyme-linked immunosorbent assay (gpELISA) and enzyme-linked immunosorbent spot (ELISPOT) assays using the interferon (IFN)-γ and interleukin (IL)-2 FluoroSpot kit 6 weeks after vaccination. Safety was monitored for 26 weeks based on subjects' diaries, spontaneous reports from subjects, and history taking by the investigators. A total of 845 subjects participated in the screening, and 823 received the vaccination (413 in the NBP608 group and 411 in the comparator group). The gpELISA-determined geometric mean fold rise from baseline to post NBP608 vaccination was 2.75 [95% confidence interval, CI (2.57, 2.94)]. The gpELISA-determined adjusted geometric mean titers (GMTs) of NBP608 and the comparator were 1346.37 [95% CI (1273.99, 1422.87)] and 1674.94 [95% CI (1585.35, 1769.58)], respectively. The adjusted GMT ratio of NBP608 to the comparator was 0.80 [95% CI (0.75, 0.87)]. There was no statistically significant difference between two groups in terms of the geometric mean spot numbers determined by IFN-γ and IL-2 ELISPOT assays at 6 weeks post vaccination (P = 0.7232, 0.3844). The incidence of adverse events (AEs) within 6 weeks post vaccination was 49.82% overall (410/823, 941 cases), 50.73% (209/412, 474 cases) in the NBP608 group, and 48.91% (201/411, 467 cases) in the comparator group. The difference in AE rate between the two groups was not statistically significant (P = 0.6010). Most AEs were mild, with a rate of 83.12% in the NBP608 group and 75.37% in the comparator group. Thus, NBP608 is non-inferior to Zostavax® in terms of inducing the immune response and can be safely administered to adults aged 50 years or older. ClinicalTrials.gov Identifier: NCT03120364.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Choi WS, Choi JH, Jung DS, et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older. Vaccine. 2019. PMID: 31122860. doi:10.1016/j.vaccine.2019.04.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。